Instylla Logo

Materializing Solutions

Instylla delivers next-generation liquid embolics for interventional radiology, with initial clinical applications in interventional oncology and peripheral hemostasis.

LatesT news

Instylla First-In-Human Clinical Trial Published Results Demonstrate Technical Success and Persistent Embolization Across All Patients

March 15, 2022

BEDFORD, Mass., March 15, 2022/PRNewswire/ — Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral vascular embolotherapy, today announced the publication of results[i] from the first-in-human clinical trial of Embrace™ Hydrogel Embolic System (HES) for the treatment of hypervascular tumors, in the Journal of Vascular and Interventional Radiology (JVIR). This prospective, single-arm […]

Read More